This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: 787 Pharmacodynamic study of serum EGFR and HER2 in patients with non-small cell lung cancer treated with ZD 1839, European Journal of Cancer Supplements, September 2003, Elsevier,
DOI: 10.1016/s1359-6349(03)90812-3.
You can read the full text:
The following have contributed to this page
